About abivax sa - AAVXF
Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.
AAVXF At a Glance
Abivax SA
7-11 Boulevard Haussmann
Paris, Ile-de-France 75009
| Phone | 33-1-53-83-09-63 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Other | Net Income | -190,639,342.28 | |
| Sector | Health Technology | Employees | 69 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
AAVXF Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 10.552 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.964 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.254 |
AAVXF Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -2,762,889.018 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
AAVXF Liquidity
| Current Ratio | 1.816 |
| Quick Ratio | 1.816 |
| Cash Ratio | 1.534 |
AAVXF Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -66.448 |
| Return on Equity | -147.47 |
| Return on Total Capital | -134.599 |
| Return on Invested Capital | -105.214 |
AAVXF Capital Structure
| Total Debt to Total Equity | 237.027 |
| Total Debt to Total Capital | 70.329 |
| Total Debt to Total Assets | 46.872 |
| Long-Term Debt to Equity | 129.179 |
| Long-Term Debt to Total Capital | 38.329 |